Hair loss treatment company Advangen International has been ordered to fork over $940,000 to advertising agency Ikon Communications after refusing to pay for an ad campaign it claimed was a flop.
Shenzen-based radio manufacturer Hytera Communications has lost a bid to circumvent its discovery obligations in an ongoing patent dispute with Motorola, with a Federal Court judge rejecting its claims that supplying the documents could breach Chinese state secret and cybersecurity laws.
A judge has ordered changes be made to the opt out notice in three class actions over the 2018 St. Patrick’s Day bushfires in South West Victoria, after insurers complained comments made by a Maddens principal to a local newspaper were misleading.
A group representing Australian winemakers has lost its objection to the European Commission’s plan to register ‘Avola’ as a mark of geographical indication for wine.
Billionaire Clive Palmer has succeeded in knocking a second judge off a case brought against him by the liquidators of failed Queensland Nickel, after arguing that a previous ruling disqualified him.
Australian coffee maker Vittoria Food & Beverage has won another challenge to a patent for a coffee pod system filed by a unit of Mondelez International.
UGL knew by April 2014 that there were delays with the Ichthys LNG project, but failed to make required disclosures to shareholders, according to an amended pleading in a shareholder class action against the engineering company.
An appeals court has rejected the funder’s commission and legal fees stemming from a $64 million settlement in litigation over the failure of Banksia Securities, but granted approval to the settlement.
The presence of a seconded Ashurst lawyer at a Fair Work Commission hearing in an unfair dismissal case against Qantas did not violate an order denying the airline’s request to hire the firm to represent it in the case, the Fair Work Commission has found.
Generic drug maker Alphapharm has lost another bid for documents from Sanofi-Aventis in advance of a hearing on Sanofi’s interlocutory application seeking to block the generic drug maker from listing its injector pen on the Pharmaceutical Benefits Scheme.